By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AVANIR Pharmaceuticals 

11388 Sorrento Valley Road

San Diego  California  92121  U.S.A.
Phone: 858-622-5200 Fax: 858-658-7447


SEARCH JOBS


Industry
Healthcare

Segment
Pharmaceuticals





Company News
AVANIR Pharmaceuticals (AVNR) Announces Presentation Of AVP-923 Phase 2 Results In Agitation In Patients With Alzheimer's Disease At The American Neurological Association Meeting 10/13/2014 11:48:33 AM
AVANIR Pharmaceuticals (AVNR) To Host Investor Briefing On October 15, 2014 10/9/2014 9:21:36 AM
AVANIR Pharmaceuticals (AVNR) Announces Data Presentations At The American Neurological Association's (ANA) 2014 Annual Meeting Including Results From The Phase 2 Trial For Treatment Of Agitation In Patients With Alzheimer's Disease 10/8/2014 8:36:43 AM
AVANIR Pharmaceuticals (AVNR) Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares 9/29/2014 10:08:58 AM
AVANIR Pharmaceuticals (AVNR) Announces Pricing Of Public Offering Of Common Stock 9/24/2014 8:16:32 AM
AVANIR Pharmaceuticals (AVNR) Announces Proposed Public Offering Of Common Stock 9/23/2014 7:51:20 AM
AVANIR Pharmaceuticals (AVNR) Rockets As Lead Drug Succeeds In Reducing Alzheimer's Related Agitation; Stock Up 63.20% At 10:19AM ET On Monday 9/15/2014 7:19:37 AM
AVANIR Pharmaceuticals (AVNR) To Present At The Morgan Stanley (MST) Global Healthcare Conference 9/2/2014 1:35:50 PM
Concert Pharmaceuticals, Inc. (CNCE) Achieves $2 Million Milestone For AVP-786 Under AVANIR Pharmaceuticals (AVNR) Collaboration 8/26/2014 9:28:38 AM
AVANIR Pharmaceuticals (AVNR) Announces Initiation Of Phase 2 Study Of AVP-786 For The Adjunctive Treatment Of Major Depressive Disorder 8/26/2014 7:32:22 AM
12345678910...
//-->